Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?

Bibliography

• Blennow K, de Leon MJ, Zetterberg H. Alzheimer's disease. Lancet 2006;368:387-403
   PubMed Web of Science ®Google Scholar
• Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med 2010;362:329-44
   PubMed Web of Science ®Google Scholar
• Lalonde R, Fukuchi K, Strazielle C. Neurologic and motor dysfunctions in APP transgenic mice. Rev Neurosci 2012;23:363-79
   PubMed Web of Science ®Google Scholar
• Morales-Corraliza J, Schmidt SD, Mazzella MJ, et al. Immunization targeting a minor plaque constituent clears beta-amyloid and rescues behavioral deficits in an Alzheimer's disease mouse model. Neurobiol Aging 2013;34:137-45
   PubMed Web of Science ®Google Scholar
• Gandy S. Molecular basis for anti-amyloid therapy in the prevention and treatment of Alzheimer's disease. Neurobiol Aging 2002;23:1009-16
   PubMed Web of Science ®Google Scholar
• Weiner HL, Selkoe DJ. Inflammation and therapeutic vaccination in CNS diseases. Nature 2002;420:879-84
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhu J, Xu G, et al. Intranasal delivery of stem cells to the brain. Expert Opin Drug Deliv 2011;8:623-32
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wei N, Lu T, et al. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience 2011;172:398-405
   PubMed Web of Science ®Google Scholar
• Hong L, Koelsch G, Lin X, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 2000;290:150-3
   PubMed Web of Science ®Google Scholar
• Citron M. Alzheimer's disease: treatments in discovery and development. Nat Neurosci 2002;5(Suppl):1055-7
   PubMed Web of Science ®Google Scholar
• Adolfsson O, Pihlgren M, Toni N, et al. An effector-reduced anti-beta-amyloid (Abeta) antibody with unique abeta binding properties promotes neuroprotection and glial engulfment of Abeta. J Neurosci 2012;32:9677-89
   PubMed Web of Science ®Google Scholar
• Wang W, Fan L, Xu D, et al. Immunotherapy for Alzheimer's disease. Acta Biochim Biophys Sin (Shanghai) 2012;44:807-14
   PubMed Web of Science ®Google Scholar
• Morgan D, Diamond DM, Gottschall PE, et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000;408:982-5
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999;400:173-7
   PubMed Web of Science ®Google Scholar
• Schenk D. Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning. Nat Rev Neurosci 2002;3:824-8
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005;64:94-101
   PubMed Web of Science ®Google Scholar
• Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008;372:216-23
   PubMed Web of Science ®Google Scholar
• Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 2002;1:3
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003;61:46-54
   PubMed Web of Science ®Google Scholar
• Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-62
   PubMed Web of Science ®Google Scholar
• Fox NC, Black RS, Gilman S, et al. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005;64:1563-72
   PubMed Web of Science ®Google Scholar
• Vellas B, Black R, Thal LJ, et al. Long-term follow-up of patients immunized with AN1792: reduced functional decline in antibody responders. Curr Alzheimer Res 2009;6:144-51
   PubMed Web of Science ®Google Scholar
• Serrano-Pozo A, William CM, Ferrer I, et al. Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain 2010;133:1312-27
   PubMed Web of Science ®Google Scholar
• Boche D, Donald J, Love S, et al. Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer's disease. Acta Neuropathol 2010;120:13-20
   PubMed Web of Science ®Google Scholar
• Robinson SR, Bishop GM, Lee HG, et al. Lessons from the AN 1792 Alzheimer vaccine: lest we forget. Neurobiol Aging 2004;25:609-15
   PubMed Web of Science ®Google Scholar
• Schenk D. Hopes remain for an Alzheimer's vaccine. Nature 2004;431:398
   PubMed Web of Science ®Google Scholar
• Chackerian B. Virus-like particle based vaccines for Alzheimer disease. Hum Vaccin 2010;6:926-30
   PubMed Web of Science ®Google Scholar
• Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011;31:9323-31
   PubMed Web of Science ®Google Scholar
• Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012;11:597-604
   PubMed Web of Science ®Google Scholar
• Kingwell K. Alzheimer disease: amyloid-beta immunotherapy CAD106 passes first safety test in patients with Alzheimer disease. Nat Rev Neurol 2012;8:414
   PubMedGoogle Scholar
• Schneeberger A, Mandler M, Otawa O, et al. Development of AFFITOPE vaccines for Alzheimer's disease (AD)–from concept to clinical testing. J Nutr Health Aging 2009;13:264-7
   PubMed Web of Science ®Google Scholar
• Weksler ME, Relkin N, Turkenich R, et al. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp Gerontol 2002;37:943-8
   PubMed Web of Science ®Google Scholar
• Gelfand EW. Intravenous immune globulin in autoimmune and inflammatory diseases. N Engl J Med 2012;367:2015-25
   PubMed Web of Science ®Google Scholar
• Dodel RC, Du Y, Depboylu C, et al. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2004;75:1472-4
   PubMed Web of Science ®Google Scholar
• Relkin NR, Szabo P, Adamiak B, et al. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2009;30:1728-36
   PubMed Web of Science ®Google Scholar
• Dodel R, Rominger A, Bartenstein P, et al. Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol 2013;12:233-43
   PubMed Web of Science ®Google Scholar
• Holmes C. Intravenous immunoglobulin for Alzheimer's disease. Lancet Neurol 2013;12:218-19
   PubMed Web of Science ®Google Scholar
• Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70
   PubMed Web of Science ®Google Scholar
• Black RS, Sperling RA, Safirstein B, et al. A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 2010;24:198-203
   PubMed Web of Science ®Google Scholar
• Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement 2011;7:367-85
   PubMed Web of Science ®Google Scholar
• Archer HA, Edison P, Brooks DJ, et al. Amyloid load and cerebral atrophy in Alzheimer's disease: an 11C-PIB positron emission tomography study. Ann Neurol 2006;60:145-7
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72
   PubMed Web of Science ®Google Scholar
• Blennow K, Zetterberg H, Rinne JO, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol 2012;69:1002-10
   PubMed Web of Science ®Google Scholar
• Vellas B, Carrillo MC, Sampaio C, et al. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force. Alzheimers Dement 2013;9:438-44
   PubMed Web of Science ®Google Scholar
• Tayeb HO, Murray ED, Price BH, et al. Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive? Expert Opin Biol Ther 2013;13:1075-84
   PubMed Web of Science ®Google Scholar
• Uenaka K, Nakano M, Willis BA, et al. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid beta monoclonal antibody solanezumab in Japanese and white patients with mild to moderate Alzheimer disease. Clin Neuropharmacol 2012;35:25-9
   PubMed Web of Science ®Google Scholar
• Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease. Alzheimers Dement 2012;8:261-71
   PubMed Web of Science ®Google Scholar
• Lachno DR, Evert BA, Vanderstichele H, et al. Validation of assays for measurement of amyloid-beta peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab. J Alzheimers Dis 2013;34:897-910
   PubMed Web of Science ®Google Scholar
• Gray LJ, Cooper N, Dunkley A, et al. A systematic review and mixed treatment comparison of pharmacological interventions for the treatment of obesity. Obes Rev 2012;13:483-98
   PubMed Web of Science ®Google Scholar
• Samadi H, Sultzer D. Solanezumab for Alzheimer's disease. Expert Opin Biol Ther 2011;11:787-98
   PubMed Web of Science ®Google Scholar
• Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: a novel human anti-Abeta antibody demonstrates sustained cerebral amyloid-beta binding and elicits cell-mediated removal of human amyloid-beta. J Alzheimers Dis 2012;28:49-69
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol 2012;69:198-207
   PubMed Web of Science ®Google Scholar
• Grundman M, Dibernardo A, Raghavan N, et al. 2012: a watershed year for. Alzheimer's disease research. J Nutr Health Aging 2013;17:51-3
   PubMed Web of Science ®Google Scholar
• Reichert JM. Which are the antibodies to watch in 2013? MAbs 2013;5:1-4
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhu W, Zhu J, et al. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of lesion artery in patients with stroke in the territory of middle cerebral artery. Cell Transplant 2012; [Epub ahead of print]
   Web of Science ®Google Scholar
• Ma YP, Ma MM, Ge S, et al. Intranasally delivered TGF-beta1 enters brain and regulates gene expressions of its receptors in rats. Brain Res Bull 2007;74:271-7
   PubMed Web of Science ®Google Scholar
• Alcalá-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO, and NT-4 to the CNS. J Drug Target 2010;18:179-90
   PubMed Web of Science ®Google Scholar
• Hashizume R, Ozawa T, Gryaznov SM, et al. New therapeutic approach for brain tumors: intranasal delivery of telomerase inhibitor GRN163. Neuro Oncol 2008;10:112-20
   PubMed Web of Science ®Google Scholar
• Bondier JR, Michel G, Propper A, et al. Harmful effects of cadmium on olfactory system in mice. Inhal Toxicol 2008;20:1169-77
   PubMed Web of Science ®Google Scholar
• Jiang Y, Wei N, Zhu J, et al. A new approach with less damage: intranasal delivery of tetracycline-inducible replication-defective herpes simplex virus type-1 vector to brain. Neuroscience 2012;201:96-104
   PubMed Web of Science ®Google Scholar
• Han IK, Kim MY, Byun HM, et al. Enhanced brain targeting efficiency of intranasally administered plasmid DNA: an alternative route for brain gene therapy. J Mol Med 2007;85:75-83
   PubMed Web of Science ®Google Scholar
• Frenkel D, Solomon B. Filamentous phage as vector-mediated antibody delivery to the brain. Proc Natl Acad Sci USA 2002;99:5675-9
   PubMed Web of Science ®Google Scholar
• Liu X. Clinical trials of intranasal delivery for treating neurological disorders – a critical review. Expert Opin Drug Deliv 2011;8:1681-90
   PubMed Web of Science ®Google Scholar